CeriBell, Inc. Announces Expanded Initial Public Offering Pricing

SUNNYVALE, Calif., Oct. 10, 2024 /PRNewswire/ — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a commercial-stage medical technology company focused on transforming the diagnosis and treatment of patients with serious neurological conditions , today announced the pricing of its expanded initial public offering of 10,606,060 shares of common stock at a public offering price of $17.00 per share. In connection with the offering, Ceribell has granted the underwriters a 30-day option to purchase up to an additional 1,590,909 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on October 11, 2024 under the symbol “CBLL.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ceribell, are expected to be approximately $180.3 million, excluding any exercise of the underwriters’ option to purchase additional shares. The closing of the offering is expected to occur on October 15, 2024, subject to satisfaction of customary closing conditions.

BofA Securities and JP Morgan are acting as joint book-running managers and representatives of the underwriters of the offering. William Blair, TD Cowen and Canaccord Genuity are acting as co-managers of the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email mail at (email protected); or JP Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at (email protected) and (email protected).

A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 10, 2024. This press release shall not constitute an offer to sell or the solicitation of a offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ceribell
Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and treatment of patients with serious neurological diseases. The Ceribell System is a rapidly deployable, AI-powered point-of-care electroencephalography (“EEG”) platform designed to address the unmet needs of patients in the critical care setting. The company is headquartered in Sunnyvale, California.

CONTACT WITH INVESTORS

Brian Johnston or Laine Morgan
Gilmartin Group, LLC
(email protected)

MEDIA CONTACT

Corrie Rosa
(email protected)

SOURCE Ceribell, Inc.